Archive

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.

Role for ESMO: Access to IO for all?

Late breaking abstracts – Checkmate 227 study

The final analyses of Checkmate 227, part 1 should help to position nivolumab + ipilimumab combination treatment .. Written by Christine Clark

SCLC: is it time for novel therapies?

The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified.  In the meantime the results of CASPIAN… read more.

Oligorecurrent and oligoprogressive NSCLC

Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion……..    Written by Christine Clark.

Immunotherapy in thoracic malignancies: what has been achieved in 2019?

Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.

Expert insights in advanced ALK-positive NSCLC

Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.

Late breaking abstracts – FLAURA study

The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.

Highlights from ESMO 2019

For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting.  Written by Christine Clark

ESMO 2019 takeaways

Interview by Esther Drain In this video, Professor Solange Peters (University of Lausanne, CH) gives us her updates from ESMO including quality of research at the meeting, how… read more.

Encouraging data in advanced melanoma

There was a lot of great news from the ESMO Congress 2019 in Barcelona for melanoma patients. Written by Esther Drain.

CAR-T cells and bi-specific agents

Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.